{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+Heparin", "query": { "intervention": "Subcutaneous Heparin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 73, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+Heparin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T09:54:59.979Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00345618", "title": "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Embolism", "Thrombosis" ], "interventions": [ { "name": "Idrabiotaparinux sodium", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo (for idrabiotaparinux sodium)", "type": "DRUG" }, { "name": "Avidin", "type": "DRUG" }, { "name": "Placebo (for warfarin)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3202, "start_date": "2006-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345618" }, { "nct_id": "NCT04401293", "title": "Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sars-CoV2", "COVID" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Prophylactic/Intermediate Dose Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2020-04-26", "completion_date": "2021-05-14", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 6, "location_summary": "Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more", "locations": [ { "city": "Newark", "state": "New Jersey" }, { "city": "Bay Shore", "state": "New York" }, { "city": "Huntington", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Queens", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401293" }, { "nct_id": "NCT05286814", "title": "PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (Mcrc)", "Intrahepatic Cholangiocarcinoma (Icc)", "Intrahepatic Bile Duct Cancer", "Colorectal Neoplasms", "Colorectal Cancer", "Cholangiocarcinoma", "Bile Duct Neoplasms", "Bile Duct Cancer", "Adrenocortical Carcinoma (ACC)", "Adrenal Cortical Carcinoma", "Adrenal Gland Cancer", "Adrenal Gland Neoplasms", "Adrenal Cortex Neoplasms" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "PDS01ADC", "type": "DRUG" }, { "name": "Intera 3000 Hepatic Artery Infusion Pump (HAIP)", "type": "DEVICE" }, { "name": "Floxuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 70, "start_date": "2022-10-24", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286814" }, { "nct_id": "NCT02206100", "title": "PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PER977", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2014-04", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206100" }, { "nct_id": "NCT07713875", "title": "Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Venous Thromboembolism (VTE)", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Spine Metastasis" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Bayley", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 3, "location_summary": "Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittburgh", "state": "Pennsylvania" }, { "city": "Pittburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07713875" }, { "nct_id": "NCT02070237", "title": "Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Obesity, Morbid", "Pregnancy", "Complications; Cesarean Section", "Venous Thromboembolism", "Postpartum Deep Phlebothrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MemorialCare Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 90, "start_date": "2013-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02070237" }, { "nct_id": "NCT04169269", "title": "Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Deep Vein Thrombosis", "Venous Thromboembolism" ], "interventions": [ { "name": "Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters", "type": "DRUG" }, { "name": "Rivaroxaban 10 milligram Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Florida Orthopaedic Institute", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2020-01-13", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04169269" }, { "nct_id": "NCT01583218", "title": "Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)" ], "interventions": [ { "name": "Betrixaban", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 7513, "start_date": "2012-03", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01583218" }, { "nct_id": "NCT02707263", "title": "Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "intravenous continuous infusion of heparin (IV UFH)", "type": "DRUG" }, { "name": "Subcutaneous Heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707263" }, { "nct_id": "NCT00679588", "title": "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Semuloparin Sodium", "type": "DRUG" }, { "name": "Enoxaparin sodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4413, "start_date": "2008-04", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2013-12-16", "last_synced_at": "2026-09-03T09:54:59.979Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Corlton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00679588" } ] }